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Zusammenfassung für Laien 
Unter dem Begriff “Nano” versteht man im Volksmund die Bezeichnung von etwas 
verschwindend Kleinem, nicht wirklich Greifbarem, vielleicht sogar etwas 
Vernachlässigbarem. Der Begriff stammt vom altgriechischen Wort „nanos“ ab, was 
übersetzt Zwerg heisst. Die Mathematik definiert den Präfix „Nano“ als den milliardsten 
Teil einer Einheit. Folglich entspricht eine Milliarde Nanometer einem Meter. 
Tatsächlich kommen wir in unserem Alltag häufig unbewusst mit Materialien in 
Berührung, welche nur wenige Nanometer gross sind. Solche Nanomaterialien sind 
essentielle Bestandteile von Verpackungsmaterialien, Computern, Kosmetika, 
Textilien und pharmazeutischen Hilfsstoffen. 1957 hielt der spätere Nobelpreisträger 
Richard Feynman einen Vortrag über eine Vision. Er behauptete damals, dass die 
Medizin der Zukunft kleinste Maschinen und Roboter verwenden werde, um 
Krankheiten zu bekämpfen und Patienten zu heilen. Diese Maschinen würden kleiner 
sein als menschliche Zellen und könnten in definierter Zahl an den richtigen Ort 
gesteuert werden. Anfang der 1970er Jahre wurden Nanopartikel (sphärische 
Nanomaterialien) erstmals als potentiell erfolgsversprechende Anwendungen für die 
pharmazeutische und medizinale Forschung diskutiert. Sechzig Jahre nach Feynmans 
Vortrag ist seine Vision bis zu einem gewissen Grad Realität geworden. Heute gibt es 
mehr als 150 Anwendungen von Nanopartikeln in der Medizin. Sie sind oft sehr einfach 
herstellbar, dienen als Träger für empfindliche Wirkstoffe, werden als Kontrastmittel 
eingesetzt und sollen in der Krebstherapie als Wirkstoffe etabliert werden. Ihre Grösse 
bringt einen entscheidenden Vorteil gegenüber herkömmlichen Arzneiformen. Genau 
wie Feynman es beschrieben hatte, sind Nanopartikel klein genug, um zelluläre 
Barrieren zu überwinden. Zudem sind sie so potent, dass ihre Dosierung tiefer als jene 
von herkömmlichen Arzneistoffen gehalten werden kann. Ein weiterer Vorteil ist ihre 
enorme Partikeloberfläche, welche chemisch meist sehr einfach manipulierbar ist. 
Dadurch können Nanopartikel so verändert werden, dass sie zielgerichtet ihren Wirkort 
finden und gleichzeitig vor dem körpereigenen Immunsystem geschützt sind. All diese 
Aspekte machen die Nanomedizin zu einem der am schnellsten wachsenden 
Forschungszweigen des neuen Jahrtausends. Jedoch birgt der grösste Vorteil der 
Nanomedizin auch ein weitreichendes Risiko. Dank ihrer Grösse weisen Nanopartikel 
oft einzigartige Eigenschaften auf, welche denselben Materialien in grösserem 
Massstab fehlen. Zudem erhöht das Verhältnis von Grösse zu Oberfläche die 
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Reaktivität von Nanopartikeln um ein Vielfaches. Die Kombination dieser speziellen 
Eigenschaften verleiht Nanopartikeln das Gefahrenpotential, eine lange Bandbreite 
von ungewollten Nebenwirkungen auslösen zu können. Man weiss heute, dass nach 
dem Kontakt mit den meisten Zelltypen, Nanopartikel sehr einfach von diesen 
aufgenommen werden können. Diese Zellen bekunden danach jedoch oft Mühe den 
Abbau und das Ausstossen der Partikel zu regulieren. Das Unvermögen diese 
Fremdkörper wieder ausscheiden zu können, löst Stress in betroffenen Zellen aus. In 
vielen Fällen führt dies zu ungewollten Immunantworten wie etwa Hypersensibilität, 
Entzündungen oder Zelltod. Bewiesen wurde auch, dass einige Partikel nach Kontakt 
mit biologischen Flüssigkeiten anfangen Klumpen zu bilden. Setzen sich diese 
Klumpen im Körper dauerhaft fest, kann das ebenfalls erhebliche Konsequenzen für 
die Gesundheit nach sich ziehen. Gelangen solche Nanopartikel z.B. in die Blutbahn, 
sind Thrombosen und Embolien sehr realistische Spätfolgen. Um dies zu verhindern, 
setzen sich Regierungen, Behörden und Gesundheitsorganisationen in 
Zusammenarbeit mit Firmen und Universitäten seit Jahren verstärkt mit der Giftigkeit 
von Nanomaterialien auseinander (Nanotoxikologie). Durch ihre Einzigartigkeit wurde 
schnell klar, dass herkömmliche Sicherheitsmassnahmen und –vorschriften nicht 
ausreichen, um das toxische Potential von Nanomaterialien zu ergründen. Zahlreiche 
Ideen und Lösungsansätze für die Nanotoxikologie sind bis heute diskutiert worden 
und die Menge an erhobenen Daten wächst täglich. Jedoch sind sich Experten in 
mehreren Punkten noch immer uneinig. Angefangen bei geeigneten Dosierungen und 
Messmethoden bis hin zur Auslegung von experimentellen Daten ist noch kein 
Vorschlag von allen Beteiligten gleichermassen akzeptiert worden. Das Hauptproblem 
besteht darin, dass die Anwendungsvielfalt von Nanomaterialien zu gross ist, um eine 
einheitliche Regulierungs- und Sicherheitsstrategie aufstellen zu können. Der zurzeit 
vielversprechendste Ansatz ist, es Nanopartikel anhand ihrer Eigenschaften oder 
biologischen Interaktionen in Sicherheitsgruppen klassifizieren zu können. Die 
medizinale Anwendung von Nanopartikeln steckt noch immer in den Kinderschuhen, 
jedoch verhindert die Abwesenheit von klar strukturierten und 
anwendungsspezifischen Richtlinien den weiteren Aufschwung dieser 
Formulierungen. 
Aus diesem Grund war es das Ziel dieser Dissertation, einen Lösungsansatz für die 
Sicherheitsevaluation von Nanomedizin-Formulierungen auszuarbeiten. 
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Als erstes wurden die Interaktionen und Reaktionen von Zellen auf unterschiedliche 
Nanopartikel analysiert und ausgewertet. Dabei lag der Fokus auf Nanopartikeln, 
deren Verwendung in der Pharmazie etabliert ist oder diskutiert wird. Anhand der 
erhobenen Daten konnten Verbindungen zwischen zellulären Reaktionen und 
bestimmten physikalisch-chemischen Eigenschaften von Partikeln bewiesen werden. 
Ebenso wurden unterschiedliche Reaktionen in verschiedenen Zelltypen beobachtet. 
Es konnte daraufhin festgestellt werden, dass das toxische Potential von 
Nanopartikeln abhängig ist von: 
• der chemischen Zusammensetzung der Formulierung, 
• den spezifischen physikalisch-chemischen Eigenschaften der Formulierung, 
• und der biologischen Umgebung der Formulierung. 
Um diese Beobachtungen im lebenden Tier zu überprüfen, wurden Nanopartikel 
mittels Injektion in die Blutbahnen von Zebrafischembryonen gespritzt. Embryonen des 
Zebrafisches sind durchsichtig und weisen ein ähnliches Immunsystem zum 
Menschen auf, was die Interpretation der Resultate vereinfachen kann. Zudem wird 
die Mehrheit aller heutigen Nano-Pharmazeutika via Injektion appliziert. Die 
embryonale Partikelverteilung und die Gesundheit des Tiers wurden anhand 
unterschiedlicher Methoden im Verlauf mehrerer Tage studiert und analysiert. Die 
Resultate erbrachten den Beweis, dass Nanopartikel bestimmte Voraussetzungen 
erfüllen müssen, um auch im Tier keine toxischen Ereignisse hervorrufen zu können. 
Unter der Berücksichtigung behördlicher Richtlinien, validierten Methoden und 
standardisierten Protokollen wurde schliesslich ein Entwurf zur ersten Strategie der 
Sicherheitsevaluation von medizinischen Nanopartikeln ausformuliert. Die Strategie 
besteht aus drei individuellen Testsystemen. Im ersten System werden die 
relevantesten physikalisch-chemischen Eigenschaften von Nanopartikeln für die 
medizinische Anwendung bestimmt und analysiert. Danach wird deren Verträglichkeit 
in einem neuartigen Gruppierungsverfahren getestet und evaluiert. Zum Schluss bietet 
die Strategie eine Sicherheitsprüfung individuell abgestimmt auf jede Gruppe. Diese 
anwendungsspezifische Strategie vereint bestehende Richtlinien mit neuartigen 
Testansätzen und ermöglicht so eine unkomplizierte, sachgerechte 
Entscheidungsfindung. 
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Summary 
In 1959, physicist and Nobel laureate-to-be Richard Feynman held his famous speech 
“There’s Plenty of Room at the Bottom”. Herein he prophesized the upcoming of a new 
research field dedicated entirely to the nanometer scale. Six decades later we find 
ourselves amid the vision of Feynman where nanomaterials are omnipresent in daily 
life. Especially engineered nanoparticles (ENP) have gained enormous interest in 
medicine showing promising potentials as novel drug carrier systems, drug entities, 
and contrast agents. However, due to their size and physico-chemical properties, ENP 
inherit a unique toxicological profile that remains poorly understood. Moreover, the lack 
of generally accepted guidelines designed specifically for ENP prevents their proper 
safety regulation and risk assessment. 
In collaboration with the Swiss Center for Applied Human Toxicology (SCAHT) and the 
Horizion2020 NanoReg2 consortium, we focused our research on establishing ENP-
specific characterization strategies and assay toolboxes that should provide robust 
information on the safety of ENP-organism interactions. 
Our results have shown that ENP toxicity is mediated by the chemical identity of a 
particle along with specific physico-chemical properties but also depends on the 
surrounding biological system. In vitro, in vivo, and in situ analyses ranging from simple 
viability studies to complex signaling pathway analysis have helped to link adverse 
effects and immune responses to different ENP types or specific properties thereof. 
Furthermore, we established the first protocol for the 3D-visualization of non-labeled 
ENP in vivo by synchrotron-radiation phase contrast x-ray micro-computer-
tomography in therapeutically relevant dose-ranges. This novel method will aid to 
better understand the behavior of ENP after intravenous injection and may serve as a 
novel platform for the monitoring of ENP biodistribution and targeting. 
Conclusively, the combined results obtained during this thesis have led to the proposal 
of a novel safety assessment strategy which specifically targets ENPs designed for 
therapeutic use. This proposal highlights the importance and the benefits of 
application-specific decision-making with a strong emphasis on physico-chemical 
characterization and in vitro hazard assessment. This strategy is meant to contribute 
to the ongoing establishment of much needed nano-specific safety guidelines and was 
developed to be in line with the interests of regulatory authorities and researchers alike.
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Introduction 
Engineered nanomaterials 
The term “nano” is derived from the ancient Greek “nānos” (νᾶνος) that translates to 
the word dwarf. In the metric system, the prefix nano denotes the billionth part of a unit. 
Nanomaterials are entities displaying physical dimensions in the nanometer range 
(10-9 m – 10-8 m). The prevailing definition of a nanomaterial was set by the 
International Organization of Standardization (ISO)1, the Organization for Economic 
Co-operation and Development (OECD)2,3, and the American Society for Testing and 
Materials International (ASTM)4. According to this definition, the term nanomaterial 
encompasses all materials with at least one external (height, length, or width) or 
internal (e.g. pores) dimension in the range of approximately 1 – 100 nm. This size 
range is referred to as the nanoscale1. Since numerous materials naturally occur in the 
nanoscale and can also be referred to as nanomaterials, the term “engineered 
nanomaterial” (ENM) is used for man-made nanomaterials only. ENM are omnipresent 
in everyday life as regular components of consumable and durable goods. Developed 
on an industrial scale, they are used in e.g. printing cartridges5, cosmetics6, toiletries7,8, 
food packaging9, water purification10, and most recently medical applications11,12. Their 
versatile use is based on physico-chemical benefits resulting from their size and shape. 
Being submicron entities, nanomaterials often display unique characteristics and 
properties that their larger sized counterparts completely lack13–15. 
Correct terminology of different nanomaterial subgroups 
Nano-objects represent a form of nanomaterials and are commonly subdivided into 
nanoplatelets, nanorods or -tubes, and nanoparticles1. Often falsely referred to as 
being synonyms, these terms describe different nanomaterials according to the 
number of external dimensions in the nanoscale (Figure I). The term nano-object is 
the synonym all nanomaterials that bare at least one external dimension in the 
nanoscale. The subgroups of nanoplatelets, nanorods or -tubes, and nanoparticles are 
all nano-objects but feature specifically one, two, or three external dimensions in the 
nanoscale, respectively. Especially the ENM subcategory of engineered nanoparticles 
(ENP) have had vast impact on nanomedical research16. Today, the majority of 
approved medical nano-applications are ENP-based. The first intentional synthesis of 
nanoparticle was successfully conducted in 187517. Michael Faraday chemically 
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reduced gold chloride, which led to the production of colloidal gold. However, the 
perception that it is a novelty to use ENP for medical purposes is not entirely correct. 
 
 
Figure I – Subgrouping of the different nanomaterials. Nanomaterials are divided by the amount of 
displayed external and internal dimensions in the nanoscale. Nanomaterials encompass all materials 
that feature at least one internal or external dimension in the required size range of 1 – 100 nm. Nano-
objects require at least one external dimension in the nanoscale. Distinct numbers of external 
dimensions at the nanoscale define the subgroups nanoplatelets (exactly one external dimension), 
nanorods or -tubes (exactly two external dimensions), and nanoparticles (all three external dimensions). 
Figure adapted from Kettiger18. 
 
From the ancient to the present – History of nanoparticles in health care 
Unknowingly, nanoparticles have been used in medicine and health care for several 
thousand years in form of colloidal gold or silver. Figure II highlights some of the 
historical milestones important for the nanomedicine of today. Historical transmissions 
dating back to the fifth century BC have indicated that the ancient Chinese and Indian 
cultures made medical use of colloidal gold19. In the same century, Hippocrates of 
Greece describes the benefit of silver dust in wound care and healing.20 First 
indications of colloidal gold synthesis were found in transcriptions of the “Quinta 
essential auri” written by Paracelsus19. He described the formulation of “potable gold”21 
by adding gold chloride and vegetable extracts to oil or alcohols changing the solutions 
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color to a distinct red. Potable gold was used for the treatment of multiple conditions 
throughout the Middle Ages, including syphilis, diarrhea, or epilepsies. 
Despite all the historical transmissions, it was not until 1900 that sub-visible particles 
were scientifically discussed to have medical relevance. According to the theory of the 
“magic bullet” by chemotherapy-pioneer Paul Ehrlich it should be possible to 
specifically neutralize specific pathogens without having to harm the pathogen host 
organism itself22. To do so, one would require the smallest of particles. At that time, 
colloidal silver was frequently used in wound healing and as an antimicrobial. With the 
discovery of the liposome in 196423 and the first in vivo studies conducted in 197124, 
research on medical ENP applications has gradually gained the attention of the global 
research community. In 1995 Liposomal doxorubicin (Doxil®/Caelyx™)25–27 was the 
first medical nanoparticle to be approved by the United States Food and Drug 
Administration (FDA). Today, ENP are gaining evermore importance in life science and 
medical research sectors due to their potential use as drug carriers, imaging agents, 
and theranostics (a formulation that combines therapeutic and diagnostic properties). 
The nanomedicine research field currently has an estimated world market value of 
approximately 140 billion US dollars and regulatory approvals of medical nano-
formulations are increasing on a yearly basis28. 
 
Figure II – Nanomedicine through the ages. Engineered nanoparticles (ENP) have been used for 
millennia by various cultures for medical purposes. The term nanomedicine however did not emerge 
until recently.  
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Benefits of engineered nanoparticles in medicine 
As previously mentioned, ENP are the most used nanomaterials in nanomedicine. 
Organic nanoparticles (e.g. liposomes, polymersomes, dendrimers and drug-polymer 
conjugates) are mostly used to enhance formulation solubility29 and are used as drug 
delivery systems (DDS)30. Inorganic nanoparticles such as gold and iron oxide 
nanoparticles find use as diagnostics or theranostic tools31,32. A plethora of other 
materials including silica33,34, cerium35, and silver36 are also studied as promising 
alternatives for drug delivery, diagnostics, and theranostics. 
Drug delivery systems (DDS) 
Since the approval of Doxil®/Caelyx™ the most important and promising application 
of ENP is seen in their use as stability enhancers and novel DDS. With several 
products in clinical use nanoparticle-based DDS have proven to feature many 
advantageous characteristics16,30. Due to their unique physico-chemical properties, 
ENP can prolong the half-life of drugs in circulation by masking them from the immune 
system of the host. Additionally, this provides the advantage of causing minimal side 
effects thereby enhancing the safety of otherwise toxic formulations. Moreover, 
modifying the surface of an ENP chemically can lead to effective drug targeting or the 
promotion of controlled drug release. To date there are over 30 approved DDS based 
on ENP16, most of them being organic (lipid37 or polymer38 based). However, inorganic 
ENP based on silica39 or gold40 for instance are attracting evermore attention in 
research41. 
Diagnostics 
ENP have been reported to be utilized as tracers and contrast agents for several 
techniques (e.g. x-ray based42, photoacoustics43, fluorescence44, MRI45). The most 
successful diagnostic applications however have been contrast agents consisting of 
heavy atom nanoparticles (e.g. gold and iron oxide ENP). Due to their high physical 
and electron density, these ENP provide high imaging contrast. Combined with the 
benefit of longer blood half-life than commonly used contrast agents (e.g. iodine46), 
lower dose administrations are enabled43. This in turn minimizes exposure and 
potential toxic effects triggered by ENP. Superparamagnetic iron oxide nanoparticles 
(SPIONs) coated with dextran or carboxydextran for example are used as liver tumor 
specific contrast agents for magnetic resonance imaging (MRI)45. More recently novel 
formulations of coated SPIONs are investigated for alternative targets and computer-
 
 
5 
 
 
tomography techniques47. Gold (AuNP) are also frequently used or investigated as 
novel contrast agents for computer tomography (CT)48,49 and MRI50. More exotic 
examples of nanoparticles discussed for diagnostics are gadolinium51, platinum52, 
tantalum53, and ytterbium54. 
Theranostics 
The goal of a theranostic treatment is combining therapeutic and diagnostic properties 
in a single formulation55. Theranostics should help to enable the use of the correct 
therapy for a distinct patient at the most beneficial time. Since it was discovered that 
ENP have the potential to be used as tracers but also display therapeutic effects, 
proposals of theranostic ENP have been constantly surfacing. The development of 
such multifunctional nanoparticles would allow immediate tracking of the therapeutic 
effect56–58. Certain approved SPION formulations show these theranostic 
characteristics59,60. These SPIONs can be traced throughout an organism by CT 
techniques and are triggered with magnetic impulses to induce hyperthermia in target 
tumor tissues. 
Nanotoxicology  
Nanotoxicology has been defined as “[…] the study of the adverse effects of 
engineered nanomaterials (ENMs) on living organisms and the ecosystems, including 
the prevention and amelioration of such adverse effects. […]”61. Their size, unique 
physico-chemical properties do not only account for a vast amount of beneficial 
properties. The same characteristics are also responsible for ENM to possess complex 
toxicological profiles. The fact that ENM may pose hazardous threats towards human 
health has been discussed continuously over the past decades. Monitoring the adverse 
effects of ENP in vitro and in vivo has brought forward an enormous amount of 
nanotoxicological data leading to a more profound understanding of ENP driven toxic 
effects. Today it is known that ENP-tissue interactions are dependent on incubation 
time and ENP dose. However, the toxicity of an ENP is driven by the chemical identity 
of the particle, the physico-chemical properties that ENP features, and the biological 
system a nanoparticle is exposed to18. 
As ENP enter an organism (e.g. via inhalation, ingestion, or injection) they will interact 
with their surroundings immediately. Nanoparticles are readily taken up by a large 
amount of different human cell types. The uptake mechanism predominantly 
endocytosis. The exact uptake route (pinocytosis or phagocytosis) is highly dependent 
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on the chemical identity of the particle, its physico-chemical properties, as well as the 
cell type62,63. Once inside a cell, nanoparticles can interact with organelles, enter the 
nucleus, change the pH of the cytosol, cause the generation of reactive oxygen 
species, activate signaling cascades, or disrupt the functionality of organelles and 
tubuli. These actions can cause a string of adverse outcomes on cellular level such as 
apoptosis, necrosis, and inflammation leading to either acute or chronic damage of the 
organism. However, due to a prevailing lack of specific ENM regulations and guidelines 
information on the underlying mechanisms triggering and maintaining ENM toxicity are 
scarce. 
Shortcomings in nanosafety evaluations 
Safety evaluation of ENM has been among the most intensely and controversially 
discussed topics linked to nanotechnology in the past two decades64–70. Classical 
toxicology and risk assessment approaches have been designed to regulate small 
molecules and bulk chemicals by authorities such as the European Chemicals Agency 
(ECHA), the United States Environmental Protection Agency (EPA), the European 
Medicine Agency (EMA), and the FDA. However, the inclusion of nanomaterials into 
these established approaches was never intended71. It is generally accepted that 
commonly used regulatory approaches do not meet the necessary requirements to 
assess the safety of ENM72. Due to these circumstances, no generally approved 
guidelines exist to specifically determine the safety of nanomedicines up to date73. 
Consequently, researchers from academia and industry have been collaborating with 
authorities to formulate strategies for nanosafety evaluations over recent years61,74–76. 
Despite these efforts several key topics remain controversial due to the 
interdisciplinary use of ENM. The countless discussions on general definitions, correct 
dosimetry, standardized measurement techniques, and ideal biological test systems 
have made it clear that regulating all ENM in the same manner is not possible. Instead 
it is the conception that regulatory guidelines on the evaluation of nanosafety should 
be tailored to fit the individual scopes of ENM. 
Grouping 
At present, a popular proposal to regulate nanosafety in an application specific manner 
is based on grouping strategies. By collecting the relevant experimental data, ENM 
can be grouped into defined classes or groups facilitating further regulatory decision-
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making. Particularly in occupational safety and healthcare this strategy has found wide 
appreciation. 
Grouping strategies are mainly based on criteria that are known to be related to the 
toxic profile of an ENM. Physico-chemical properties, exposure, or cellular effects are 
the most frequently used criteria for nanosafety evaluations. Designing grouping 
strategies that are tailored to fit specific ENM exposure scenarios can further improve 
risk assessment and the regulation of nanosafety. However, nanomedicine specific 
grouping strategies and risk assessment approaches have not been proposed so far. 
Consequently, grouping strategies with a focus on ENP administration via injection 
have also been widely neglected. 
Nanoparticles used throughout this thesis 
Various types of ENP were used throughout present thesis (Figure III). Choice of ENP 
was driven by the decision to work exclusively with nanoparticles that are currently 
used as approved nanomedical formulations or regularly discussed in nanomedical 
research. Due to the focus on nanotoxicology and nanosafety, a greater variety of 
inorganic ENP were studied than their organic counterparts which are proclaimed to 
be less toxic. Silica, gold and PLGA nanoparticles were all synthesized in-house. Iron 
oxide nanoparticles were synthesized and provided by collaborators. 
 
Figure III – Nanoparticles used throughout the thesis. This figure shows transmission electron (TEM) 
micrographs (panels A, C D, E, F) and confocal laser scanning microscopy (CLSM) images (panel B) of 
all ENP discussed and studied in this thesis. The different panels show silica nanoparticles (panel A), 
fluorescent silica nanoparticles (B), gold nanoparticles (panel C), superparamagnetic iron oxide particles 
(panel D), mesoporous silica nanoparticles (panel E), and PLGA nanoparticles (panel F). Scale bars: 
panel A: 800nm, panel B: 2000nm, panel C: 25 nm, panel D: 300 nm, panel E: 200nm, panel F: 400 nm.   
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Silica nanoparticles (SiNP, MSN) 
Specific types of silica nanoparticles (Aerosil®) are extensively used as anti-caking 
agents enhancing the flowability in various pharmaceutical formulations (e.g. tablets 
and syrups). In recent years nonporous SiNP34,39,77 and mesoporous SiNP (MSN)78–80 
have been continuously discussed as novel DDS and imaging probes. Nevertheless, 
their use should be carefully monitored as SiNP and MSN can cause a plethora of 
cytotoxic effects62,81–85. In contrast to other oxide nanoparticles however, the 
degradation (silicic acids) products of SiNP and MSN are regarded to be nontoxic86. 
SiNP were synthesized in a accordance to the Stöber method established in 196887. 
This sol-gel reaction has become the standard procedure for the synthesis of 
nonporous, spherical, and uniformly sized SiNP, otherwise referred to as Stöber 
nanoparticles. By adding ammonia to a mixture of specific amounts of a alkoxysilane 
(typically tetraethyl orthosilicate (TEOS)), water, hydrolysis of the silane to silanol is 
triggered. The silanol monomers then condensate to form siloxane bonds from which 
eventually the SiNP start to grow based on the phenomenon named Ostwald 
ripening88. Different fluorescent labels (e.g. fluorescein isothiocyanate (FITC) and 
tetramethylrhodamine isothiocyanate (TRITC)) can also be introduced during the 
Stöber method by following the chemical procedure Branda et al.89 have described. 
MSN were synthesized according to the synthesis of Porta et al.90. Here, porosity was 
achieved by using the soft template surfactant hexadecyltrimethylammonium bromide 
(CTAB) as structural basis. The surfactant was removed after nanoparticle formation 
by acidic refluxing, which yielded the porous structure of the MSN. 
Gold nanoparticles (AuNP) 
Colloidal gold has been used for millennia in the treatment of physical and mental 
complaints. Today AuNP are mainly approved as diagnostic tools. They are used as 
contrast agents for x-ray and magnetism based radiology techniques such as CT and 
MRI91,92. Future applications also see AuNP introduced as theranostic tools93 or drug 
carriers40. Gold nanoparticles are often regarded as inert, stable, and relatively safe 
ENP94. However caution must be taken as these particles are only slowly excreted and 
by these means can cause adverse outcomes due to biological persistence and 
agglomeration94,95. 
At present, two procedures are used more frequently than any other to synthesize 
AuNP. Both the Brust synthesis96 and the Turkevich synthesis97 rely on redox 
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chemistry to obtain colloidal gold. In both procedures Au3+ is reduced to elemental Au0, 
but the reduction process is different. The AuNP used in this thesis were synthesized 
according to Turkevich due to the advantage of not having to use capping agents to 
prevent particle aggregation98. After dispersing tetrachloroaurate in water, Au3+ is 
reduced in the aqueous phase by adding trisodium citrate to the boiling dispersion. 
Additionally, the citrate in solution acts as the capping agent, largely preventing 
aggregation of the AuNP. 
Superparamagnetic iron oxide nanoparticles (SPIONs) 
The applications and benefits of SPIONs in nanomedicine have been highlighted 
earlier in present work. SPIONs are similarly used as gold nanoparticles and have 
become increasingly important for nanomedical applications due to their unique 
magnetic properties59,60,99. Toxicity-wise however SPIONs bare a higher risk than gold 
nanoparticles. Used for hyperthermia treatment of tumors59, these ENP can cause a 
string of adverse effects leading to cytotoxicity100–102. Moreover, SPIONs are only 
stable in an aqueous surrounding if they are coated or their surface is altered103,104. 
Should this coating be stripped off or degrade before excretion the iron oxide core will 
disintegrate105, releasing potentially harmful iron ions106. 
The SPIONs used throughout this thesis were synthesized under GMP conditions at 
the University of Erlangen by collaborators from the research group of Prof. Christoph 
Alexiou who are leading experts in the research on the applicability of SPIONs as 
nanomedicines107. 
Poly(lactide-coglycolide) (PLGA) nanoparticles 
Poly(lactide-coglycolide) (PLGA) nanoparticles are organic ENP that have attracted 
considerable attention in the nanomedicine field. Due to the biocompatibility and 
biodegradability, FDA and EMA have approved the use of PLGA-based formulations 
for drug delivery16,108. Further benefits of PLGA nanoparticles are protection from 
degradation, enabling of sustained release, and straightforward surface 
modification108,109. In nanotoxicology and nanosafety studies they can be occasionally 
used as negative controls for the occurrence of toxic events and adverse effects. 
Synthesis of poly(lactide-coglycolide) PLGA nanoparticles is generally achieved by 
mixing solutions of PLGA and di- and polymerized triacylglycerols (DPTG) to an 
emulsion with subsequent removal of the organic solvent110. 
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The PLGA nanoparticles used throughout this thesis were additionally coated with 
alternating layers of polyelectrolytes covering a layer of immobilized enzymes (acid 
phosphatase or β-galactosidase)111. PLGA is an FDA approved biodegradable 
polymer of the aliphatic polyester family frequently used in drug delivery systems109. 
Originally used for the proof of concept of a new and improved crosslinked layer-by-
layer (cLbL) concept, these ENP were also the subject of in vitro and in vivo nanosafety 
trials111. 
Physico-chemical characterization 
In comparison to the characterization of small molecules – consisting mainly of 
chemical identity and purity determination – ENP require a far more demanding 
characterization process112. 
 
Figure IV – Possibilities of ENP physico-chemical characterization. This diagram highlights the six 
most important physico-chemical parameters that can be measured for any ENP (chemical identity, 
granulometry, morphology, polydispersity, topography, and stability). Furthermore, the most frequently 
used measuring methodologies (microscopy, spectroscopy, light scattering, x-ray diffraction, 
centrifugation, gas adsorption analysis) and their respective techniques were listed to emphasize that 
there are multiple possibilities to characterize ENP. 
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Arguably the most crucial part of nanosafety; profound physico-chemical 
characterization of ENP is therefore mandatory prior to the performance of 
toxicological studies3,113. Physico-chemical characterization should also be performed 
with purchased ENP to evade incorrect evaluation of characterization dependent data. 
Chemical identity (chemical composition), granulometry (particle size), morphology 
(shape), polydispersity (size distribution), topography (surface properties), and stability 
(aggregation, agglomeration, sedimentation, disintegration) are regarded as the six 
most important physico-chemical characteristics of any ENP as they all clearly define 
the toxic potential a nano-formulation (Figure IV). These parameters should be 
provided in any study discussing effects of ENP on biological systems. However, 
certain properties may add to this short list depending on the inspected ENP and the 
intended goal of the study (e.g. magnetism114, purity115). 
 
Chemical Identity 
The chemical identity or chemical composition lays the basis to the palette of physico-
chemical properties an ENP can inherit. Determining the chemical identity of an ENP 
is most frequently done with inductively coupled plasma mass spectroscopy 
(ICP-MS116). Despite being used frequently; this technique is not suitable for all types 
of ENP. 
Granulometry (particle size and hydrodynamic diameter) 
Size is the most important property of an ENP as the shear definition of a nanoparticle 
is dependent on the nanoscale. Moreover, size also defines the prominence of certain 
physico-chemical properties. A wide range of techniques are available to measure the 
granulometry of an ENP in the dry (particle size) or dispersive state (hydrodynamic 
diameter) all bearing their own benefits and limitations. Depending on the aim of further 
downstream experiments, one of the two parameters is more relevant than the other. 
Microscopy techniques such as transmission electron microscopy (TEM117), scanning 
electron microscopy (SEM118), and atomic force microscopy (AFM119) are most 
frequently used to determine the particle size of an ENP. These techniques allow the 
visualization of single particles at high resolutions. However, due to the size of a 
micrograph and the need of relatively high particle numbers for statistical analysis, 
these techniques are usually time consuming. In recent years small angle x-ray 
scattering (SAXS120) has been promoted as an alternative method for particle size 
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measurements as well. It provides similar particle size results as TEM in less time, 
however SAXS does not render micrographs of the samples. 
There is a significant difference between ENP size in dry versus dispersive state. In 
the dry state, the actual particle size can be measured. In the dispersive state, a layer 
of bulk liquid surrounding the ENP is considered during the measurement procedure 
as well. This is due to the light scattering based measurement technique and Brownian 
motion of the ENP in dispersion. This size is commonly referred to as the hydrodynamic 
diameter. To determine the hydrodynamic diameter of ENP the gold standard method 
is dynamic light scattering (DLS121). It provides statistically significant data fast, yet 
DLS is not as accurate as TEM. A rather novel technique is nanoparticle tracking 
analysis (NTA122) for dispersed ENP. NTA is basically a combination of DLS and 
microscopy. 
Polydispersity (size distribution) 
Polydispersity is practically always measured simultaneously to granulometry. The 
polydispersity index (PDI) is a dimensionless value between zero and one123, that 
indicates how narrowly ENP size is distributed within one batch. High size distributions 
(> 0.2) indicate multiple ENP size populations in the sample, low values (< 0.2) of size 
distribution suggest the presence of only one size population. This is referred to as a 
monodisperse formulation and is often the aim in ENP syntheses. The standard 
measuring techniques are DLS124, NTA122, and TEM125. Drawbacks for TEM are the 
same as described for size measurements. The main shortcoming of DLS and NTA 
lies in the intensity-weighted analysis. Due to the dependence of scattered light, larger 
particles cause stronger signals which distort the size distribution results by a factor of 
106 as compared to number distributions121. 
Morphology (Shape) 
The morphology of ENP greatly influences their potential of exerting mechanical 
damage or being recognized by the immune system of an organism. Shapes with 
distinct edges are more likely to cause adverse effects than spherical formulations. 
Due to its definition, an ENP is shaped spherically or elliptic in most cases. The 
morphology of ENP can also be simultaneously measured to its size using microscopy 
techniques (TEM, SEM, AFM). 
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Topography (Surface) 
Topography measurements bare information on the most exposed part of an ENP. The 
surface of an ENP is prone to encounter biological matter and therefore has a direct 
effect on the immediate surroundings. Parameters such as surface area, surface 
charge (zeta potential), and surface modifications (e.g. porosity) all influence tissue-
ENP interactions. 
The measurement techniques of choice for surface area and zeta potential are gas 
adsorption analysis (BET)126 and electrophoretic light scattering (ELS121), respectively. 
BET analysis is based on measuring the amount of nitrogen desorption upon 
vaporization. Porosity and surface area can thus be calculated. ELS is based on the 
same technique electrophoresis and depends on the electrophoretic mobility of an 
ENP. The migration of ENP from one charged electrode to the oppositely charged one 
yields information on the surface charge of a nanoparticle. After ENP dispersion, ions 
from the solvent interact with the particle covering its surface entirely (Stern layer). 
During ENP movement the stern layer and a second ion layer (slipping plane) move 
with the ENP. The charge measured at the boarder of the slipping plane is the zeta 
potential. The zeta potential mainly serves as an indicator of ENP stability. A commonly 
used rule of thumb states that zeta potentials < -30 mV or > +30 mV indicate stability 
of an ENP in dispersion. It should be noted that the pH and the ion strength of a 
dissolution greatly influence the zeta potential. Without an indication of the pH value or 
the buffer used, zeta potential measurements are meaningless. 
Furthermore, ENP surfaces can be altered with countless modifications (tracers, 
targeting molecules, coatings). There are numerous techniques to verify and inspect 
these modifications. The most common techniques are fluorescence correlation 
microscopy (FCS)127,128, solid – state nuclear magnetic resonance (NMR)18, ICP-
MS116, and Fourier-transform infrared spectroscopy (FT-IR)129. It should be noted that 
each of these techniques can only be used for specific ENP types or surface 
alterations. They cannot be chosen at will (in most of the cases). 
Stability (Aggregation, Agglomeration, Sedimentation, Disintegration) 
As medical ENP occur foremost in a dispersive state, colloidal stability is a key 
parameter to be determined. Stability of an ENP provides a decent shelf-live, 
minimizes undesired immune responses, facilitates circulation, and enhances 
bioavailability. Aggregation, agglomeration, or disintegration are often results of 
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coating abrasion due to the momentary environment of the ENP. This can lead to the 
triggering of adverse effects, sedimentation, mechanical tissue damage, immune 
reactions, and ENP elimination. Formulations such as SiNP, SPIONs, silver or copper 
nanoparticles all tend to aggregate or disintegrate over time in biological fluids. 
Monitoring these processes helps to determine the safety of a given ENP in solution. 
Furthermore, suitable optimizations can be chosen according to the behavior of the 
nanoparticle to minimize potential toxic effects. 
Stability testing is often done by using DLS however there are several alternative 
methods such as ICP-MS, SEM, TEM, UV-vis spectroscopy, and analytical ultra-
centrifugation (AUC)130. 
The controversy of the biocorona 
Despite the importance that physico-chemical properties have on the toxic potentials 
of ENP, these properties can be dramatically altered as soon as ENP come in contact 
with biological fluids131–133. This alteration is commonly referred to as the 
biocorona134,135. It is supposed to be unique for every type of ENP and is often 
mentioned as a novel target to enhance the efficacy and safety of nanomedicines24,136. 
As biomolecules continuously adsorb to the surface of an ENP they eventually cover 
it entirely, masking its original synthetic surface. Consequently, ENP-tissue 
interactions are then driven by the amount and identity of adsorbed proteins and lipids 
forming the biocorona. However, the actual influence of the biocorona on toxicity is 
controversially discussed. The uncertainty of whether this biological coating is a 
dynamic or stable system has provoked more questions than brought forth answers 
concerning nanosafety. Amongst many more, Savolainen et al. have therefore 
proposed regular and careful characterization of the biocorona to further elucidate its 
impact on ENP behavior76. Even though multiple research groups have dedicated their 
work solely to the biocorona, at present there is no measuring technique that can 
determine the composition of the biocorona with significant accuracy. Thus, it is 
important to note, that the presence of the biocorona is widely accepted. Moreover, the 
determination of distinct parameters (particle size, zeta potential and stability) of ENP 
in biological fluids can indeed yield advantageous information on their behavior in in 
vitro and in vivo studies. However, if the biocorona cannot be accurately characterized, 
its impact remains hard to interpret during the evaluation of nanotoxicological results. 
Nevertheless, its presence can be appreciated by stating the following: 
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The unique physico-chemical characteristics of an ENP define the composition of its 
own biocorona. These characteristics therefore indirectly drive the influence of the 
biocorona on the behavior of the ENP. Thus, explicit correlations of the behavior and 
possible adverse effects of an ENP to its physico-chemical characteristics are correct, 
keeping in mind that these characteristics are directly responsible for the effects of the 
biocorona. 
Nanotoxicological studies 
The first documented nanotoxicological study was performed in 197124. It consisted of 
an investigation of the behavior and effects that liposomal formulations have in vivo. 
Thereupon the authors could declare that the examined formulation did not show any 
signs of adverse effects and could therefore be regarded as safe. 
Contemporary nanotoxicological studies mostly follow a three-tiered procedure. After 
physico-chemical characterization (Tier 1) cellular or animal model systems are 
exposed to ENP whereby crucial information on ENP-tissue interactions is retrieved 
(Tier 2). After completion of the data retrieval processes, the obtained results are 
analyzed and evaluated (Tier 3). Variations in ENP doses, exposure times and 
biological test system lead to a more sophisticated insight into the behavior of the ENP 
and its resulting impact on the surrounding tissues. Such insights may allow the 
correlation of observed adverse effects to specific physico-chemical properties of the 
tested ENP. By indicating that certain ENP properties trigger tissue interactions or 
adverse reactions, an initial estimate on the toxic potential of an ENP can be made. 
Elucidating the toxic potential of an ENP is the ultimate goal of any nanotoxicological 
study. The common starting point of investigating the toxicity of an ENP is determining 
its cytotoxicity in appropriate in vitro systems. The toxic potential of an ENP is not only 
unique because of its physico-chemical properties or chemical identity, its impact also 
depends greatly on the exposed biological system. In this sense, appropriate in vitro 
systems are cell-based systems that try to simulate the most probable surrounding of 
a nanoparticle in an in vivo situation. 
Throughout this thesis the focus is set on ENP designed for therapeutic applications. 
The most popular administration route for nanomedicines is injection. After injection, 
nanomedical formulations are required to circulate throughout the vasculature and exit 
the bloodstream to reach its intended target within an organism without provoking 
immune reactions. Thus, the cell types which are primarily exposed to ENP encounters 
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and interactions during are blood cells (e.g. erythrocytes, leukocytes, platelets) and the 
cells lining the inner surface of the vasculature (endothelial cells). Nanotoxicological 
studies conducted in the scope of this thesis were mainly restricted to two different 
endothelial cell types: human blood-brain barrier cells (hCMEC/D3) and primary 
human umbilical vein endothelial cells (HUVEC). Macrophages are known to take up 
ENP via phagocytosis. These interactions have been extensively discussed in a 
comparative study with erythrocytes and non-phagocytotic cells by Kettiger et al.81 
 
 
Figure V – Cellular uptake of nanoparticles over time. Time dependent cellular uptake was visualized 
by confocal microscopy using fluorescent (FITC) labeled SiNP− (100 μg/ml). Incubation times for human 
blood-brain barrier cells (hCMEC/D3, panels A–C) and primary human umbilical vein endothelial cells 
(HUVEC, panel D–F) were 0 min, 35 min, and 4 h. Actin (red) was stained using Phalloidin-Rhodamine. 
Cell nuclei (blue) were stained using Hoechst 33342. Scale bars: 100 μm. 
 
Cytotoxicity 
The impact of different ENP on cellular uptake, cellular viability, apoptosis & necrosis, 
generation of reactive oxygen species (ROS), and the triggering of different signaling 
pathways can be monitored by various techniques62. In every experiment ENP doses 
and exposure times should be varied in order to analyze the dose and time dependent 
dependence of ENP toxicity. Cellular uptake monitored over time ensures that later 
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detected toxic effects are a result of ENP uptake. These measurements can be 
conducted with confocal laser scanning microscopy (CLSM)137, flow cytometry138, and 
TEM128. Cell viability is one of the most meaningful determinants and can be monitored 
using the MTT assay139,140. This is a colorimetric technique based on NAD(P)H-
dependent enzyme activity in viable cells which – despite its limitations141,142 – features 
as one of the standard assays in nanotoxicology. Determining the present mechanism 
of cell death is highly relevant in nanotoxicology as the endpoints apoptosis and 
necrosis are understood to be triggered by different upstream-processes143. Apoptosis 
and necrosis events are commonly distinguished using fluorescent markers detected 
by CLSM or flow cytometry. Widely respected as one of the driving forces of 
nanoparticle toxicity, the generation of ROS is often discussed upon ENP uptake144. 
The DCFDA assay145 represents the most frequently used technique to monitor the 
generation of ROS. Upon oxidative stress, a green dye is oxidized intracellularly to the 
fluorescent dichlorofluorescein (DCF). However, due to its relatively low sensitivity to 
different types of ROS an alternative approach using flow cytometry is advised62. 
Oxidative stress is often accused of being the main trigger of acute ENP toxicity. ROS 
are thought to promote apoptotic but also necrotic events in vitro. Moreover, the 
overproduction of ROS is supposed to cause inflammatory responses and other 
immune reactions. To clarify these proposals, enzyme-linked immunosorbent assay 
(ELISA)146, flow cytometry, confocal microscopy, or western blot are adopted to 
investigate certain signaling pathways linked to the events of oxidative stress, 
apoptosis, necrosis and cellular defense62. The experimental methods used 
throughout this thesis are discussed in detail in the appropriate chapters (Chapters I 
– IV) of the section Results (pages 23 – 119). 
Gaining the information on these parameters upon ENP interaction will help to 
distinctively link specific ENP properties to observed adverse effects. These insights 
can thus be indispensable for risk assessment and safety regulation. However, one 
must keep in mind that in vitro results cannot simply be extrapolated to the behavior of 
ENP in vivo63,64. In vitro studies are suitable to investigate mechanistic processes and 
serve as a first line safety assessment tool. In vivo studies on the other hand are crucial 
to verify the toxic phenomena encountered in vitro. Furthermore, in vivo studies have 
the advantage of monitoring the impact of an ENP on an entire organism over the 
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course of weeks (chronic toxicity), whereas in vitro studies offer confined systems 
observable for days (acute toxicity). 
The choice of the appropriate animal model 
Continuously emerging discoveries in the fields of nanotoxicology and nanomedicine 
have urged researchers to shift from mainly using nano-specific in vitro assays to 
incorporating combinations of in vitro and in vivo assays for their nanosafety research. 
This has led nanotoxicology from being an observational science to an upcoming 
predictive science76,147. In nanotoxicological research, the most commonly used 
models are the water flea (Daphnia pulex), fruit fly (Drosophila melanogaster), and the 
vertebrate models rat, mouse, and dog. Regarding the extrapolation of medically 
relevant data to the situation in humans, the animal models water flea and fruit fly are 
not feasible. However, the immense costs and limitations accompanying the use of 
otherwise common animal models for medical purposes has opened the discussion of 
implementing a “first-line” in vivo model specifically for nanosafety. Such a model 
should enable high-throughput screening (HTS) in a cost and time-effective manner 
bridging the gap between in vitro and higher in vivo model systems. One of these 
anticipated model organisms is the zebrafish embryo (Danio rerio), which is used 
recurrently in developmental biology. 
The zebrafish is a fresh-water organism native to the Himalayan region148. It is a well-
established model system in developmental biology and a promising in vivo model 
system for toxicology studies149,150. The zebrafish embryo is not a mammal, yet it is a 
vertebrate with a close homology to the genome of a human, especially pronounced in 
the development of the immune system, blood brain barrier, and endothelial cells151–
153. This promising animal model inherits several other advantageous characteristics 
in comparison to routinely considered animal models in medical research. The most 
important benefits for nanotoxicological studies are its fast development154 (Figure VI), 
low husbandry costs, and whole-body transparency in early life stages, allowing for 
real time microscopic in vivo examination155,156. Furthermore, the zebrafish embryo has 
a size of only a few millimeters and is therefore routinely used in HTS screenings of 
developmental and ecotoxicological studies. Furthermore, the zebrafish embryo 
animal model does not fall under any official ethics guidelines regarding animal testing 
before reaching an age of 144 hours post fertilization (hpf). 
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Figure VI – Developmental stages of the zebrafish embryo. The development of a zebrafish embryo 
throughout the first two days post fertilization is documented in this figure. Zebrafish depicted at the 
1000 cell state at 3 hours post fertilization (hpf, shown in panel A), at the 21-somite state 19 hpf (panel 
B),at the prim-6 state 25 hpf (panel C), and the long-pec state 48 hpf (panel D). Scale bars: 350 µm 
Zebrafish embryo in nanotoxicology 
Assessing toxicity of ENP using the zebrafish requires ENP exposure via incubation or 
via injection. Toxicity is often assessed semi-quantitatively by monitoring embryo 
survival, motility, or the severity of phenotypic and morphological anomalies by staining 
the areas or structures of interest157–159. With regard to monitoring the safety of 
therapeutically relevant ENP, injection is preferred over incubation due to controlled 
dosimetry. Microinjection is predominantly performed into the the Duct of Cuvier (DoC), 
a temporal vascular structure running along the yolk sac on both sides of the embryo 
connecting the heart to the dorsal aorta. In Figure VII the recurrently used assays and 
visualization techniques of toxicity in zebrafish embryos are highlighted for the entire 
animal as well as the head separately. Bright field microscopy techniques allow the 
monitoring of anomalies or mutations such as edema of the heart, yolk sac 
deformation, or cartilage malformation (Fig. VII, A panels). Additionally, the abundance 
of transgenic lines (approximately 5000 individual Tg lines) offers a plethora of targets 
to choose from. 
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Figure VII – The zebrafish embryo animal model in nanotoxicology. Bright field microscopy of wild 
type AB/TU embryos for monitoring malformations (large panel A) and cartilage anomalies (small panel 
A). Confocal microscopy of transgene (Tg) kdrl:EGFP embryos with fluorescently labeled vasculature 
(large panel B) and Tg mpeg1:Gal4;UAS:Kaede embryos with fluorescently labeled macrophages (small 
panel B) for biodistribution and toxicity assays (e.g. cell death and oxidative stress). Visualization of 
green (large panel C) and red (small panel C) fluorescent SiNP (FITC and TRITC modification) for 
biodistribution, targeting and stability monitoring. Absorption contrast µCT data reconstructions of wild 
type AB/TU embryos (large panel D) with highlighted otoliths (crystalline calcium carbonate structure of 
the inner ear) (small panel D) for novel non-invasive tracing techniques and targeting approaches. 
Fluorescent microscopy techniques such as CLSM and light sheet microscopy enable 
investigations of immune reactions (macrophage migration, apoptosis) or simply the 
accentuation of certain internal structures such as the vasculature (Fig. VII, B panels). 
Moreover, fluorescent microscopy techniques enable the tracing of fluorescently 
labeled ENP throughout the entire body of the fish (Fig. VII, C panels)160. Finally, X-ray 
based techniques such as CT, µCT, and synchrotron radiation µCT (SRµCT) are the 
subject of ongoing research for the visualization of non-labeled ENP and monitoring of 
ENP biodistribution in vivo (Fig. VII, D panels). Despite its portfolio of beneficial 
characteristics and the promising outlook of emerging as novel model organism for 
nanotoxicology, the zebrafish embryo still has to prove validity in a series of more 
advanced studies.  
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Aim of the thesis 
The emergence of engineered nanoparticles (ENP) in medical applications has raised 
multiple concerns about their safety. However, there is a shortage of generally 
accepted guidelines regulating the safety of ENP designed for therapeutic use. 
Consequently, the aim of this thesis was to elucidate the interplay of key factors that 
drive nanoparticle-specific toxicity and develop a novel application-based safety 
assessment strategy for therapeutic ENP. Major project milestones were defined as 
follows: 
 
Synthesis of inorganic nanoparticles used in therapeutic research 
• How are silica and gold nanoparticles produced? 
• How can these ENP be modified for nanotoxicological studies? 
 
Physico-chemical characterization of ENP 
• How relevant is physico-chemical characterization for toxicological studies? 
• Which physico-chemical properties must be routinely determined? 
 
In vitro screening of ENP toxicity 
• How does one screen the toxicity of an ENP in vitro? 
• What toxic outcomes triggered by ENP should be screened for hazard and safety 
assessment? 
 
Alternative in vivo screening tool for nanotoxicology 
• Is the zebrafish embryo a valid alternative in vivo model for nanotoxicology? 
• Can biodistribution of non-labeled ENP be monitored in the zebrafish embryo? 
 
Shortage of safety guidelines for nanoparticles designed for therapeutic use 
• What are the most important aspects of determining the safety of ENP? 
• Is there a possibility of establishing application-based guidelines for ENP? 
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Discussion 
The versatility of ENP has made these materials promising candidates for use as novel 
drug delivery systems, imaging tools, or active agents. However, these versatile 
materials are also capable of provoking multiple adverse effects. The assessment of 
ENP safety is therefore an ongoing concern among researchers and authorities alike. 
ENP are equipped with an exceptional array of physico-chemical properties that lead 
to the inheritance of their toxicological potential. As size can influence the display of 
these properties, the hazardous health risk of every ENP is potentially unique. To 
understand how an ENP is received by tissues (Chapter I; pages 23 – 35) or 
organisms (Chapters II & III; pages 36 – 45 & 46 – 74) upon administration and 
interaction, three general parameters need to be determined. These parameters are 
the chemical identity of the particle, its physico-chemical properties, and the biologic 
system they encounter. In terms of research this requires the characterization of an 
ENP, the monitoring of its cytotoxicity, and the investigation of the behavior of an ENP 
in an entire organism (Figure VII). Furthermore, these investigations should be carried 
out in the most reproducible manner possible to avoid contradicting results and 
controversial perceptions of nanosafety. How to conduct such investigations effectively 
is one of the most discussed topic in nanosafety. The content of this thesis was 
therefore committed to further improve the knowledge of nanotoxicology (Chapters I 
& II; pages 23 – 35 & 36 – 45) and expedite the assessment of nanosafety regulation 
(Chapters III & IV; pages 46 – 74 & 75 – 119), especially for the field of ENP designed 
for therapeutic use. 
 
 
Figure VIII – Workflow in nanotoxicological research. Characterization, cytotoxicity, and in vivo 
toxicity monitoring are a prerequisite of determining the mechanism and impact of specific nanoparticle 
toxicity. Due to the lack of guidelines, the diversity of investigational set ups and interpretations of these 
three parameters have led to controversial points of view on how to correctly determine nanosafety.  
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Synthesis of inorganic nanoparticles used in therapeutic research 
Described as a major benefit, the synthesis of many ENP is often referred to as 
straightforward and highly reproducible. Indeed, an ENP can be chemically tailored to 
fit a vast amount of needs. Specific organ or tissue targeting methods such as the 
approach of hepatocyte targeting by using asialofetuin-conjugated liposomes161 are 
greatly dependent on ENP surface modifications162. The implementation of fluorescent 
markers is a further, routinely used modification of ENP surfaces for in vitro and in vivo 
observations of e.g. cellular uptake, or stability as shown in Chapter I (pages 23 – 35). 
However, most often ENP surfaces are altered to enhance the biocompatibility of these 
materials. Despite well-documented chemical procedures on how to produce ENP, the 
aspect of safety by design is often neglected. This is because many of the commonly 
used ENP syntheses were initially not intended to result in products for medical 
research87,97. Only since nanomedicine has become increasingly interesting did the 
issue of safety by design become more important. Hence modifications are routinely 
done to ensure better tolerability of ENP by a target organism. Polyethylene glycol 
(PEG) is an FDA approved polymer that is most frequently used for this purpose due 
to its high solubility and biocompatibility163. Other are options of coating being applied 
are dextran164 and human serum albumin (HSA)60 as used in Chapter III (pages 46 – 
74). 
Although straightforward synthesis approaches are common, high reproducibility 
between batches of any nanoparticle is not guaranteed. Reproducibility of ENP is often 
dependent on parameters such as temperature, pressure, purity of the reactants, 
sterility, reaction time, and the researcher performing the synthesis. In research 
laboratories, these limitations can seldom all be covered. If in these cases the physico-
chemical properties of ENP are not determined after every synthesis, false 
interpretations of further downstream results are inevitable. 
Physico-chemical characterization of ENP 
The physico-chemical characterization of an ENP marks the starting point of both 
nanotoxicological research and nanosafety assessments alike. Because the toxic 
potentials of ENP are highly dependent on their unique physico-chemical properties, 
thorough characterization is key to understand the outcome of in vitro or in vivo studies. 
In Chapter IV (pages 75 – 119) seven physico-chemical properties were defined as 
the most important parameters to be determined for therapeutic ENP candidates: 
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chemical identity, zeta potential, aqueous stability, particle size, shape, size 
distribution, and purity. 
The chemical identity, zeta potential and aqueous stability of an ENP should be among 
the first determined characteristics. Knowing the chemical identity of a formulation can 
already give important insights into the behavior and reactivity of an ENP formulation. 
Additionally, zeta potential and aqueous stability are indicators for agglomeration, 
aggregation, and sedimentation. Furthermore, negative zeta potentials have proven 
the inheritance of a lesser toxic potential than their positive counterparts. 
The key physico-chemical characteristic of an ENP however, is undoubtedly its size. 
Not only is the definition of a nanoparticle entirely size-dependent; but small size mostly 
correlates to facilitated cellular uptake, low persistence, and cytotoxicity, as well as 
lesser elimination due to phagocytosis. Moreover, an adjustment of the nanoscale 
specifically for therapeutic ENP would be beneficial as nanoparticles are taken up by 
endocytosis at larger sizes than 100 nm. The new proposal discussed in Chapter IV 
(pages 75 – 119) sees this upper limit being raised to 500 nm marking the size 
boundary where no endocytosis apart from phagocytosis takes place. 
As nanoparticles are also three-dimensional objects, size distribution and shape are 
two additional characteristics that influence the toxicity of an ENP or its readout. ENP 
are mostly regarded as being spherical. By definition however, a nanoparticle is not 
obliged to any shape but must have an aspect ratio of ≤ 3:1. Nevertheless, the aim of 
synthesizing spherical ENP should be pursued since this is the shape that minimizes 
immune responses and maximizes the circulation half-life. Size distributions should be 
kept as narrow as possible. First, to ensure that the size of a formulation remains within 
the nanoscale, secondly, narrow size distributions allow for better allocation of adverse 
effects to specific ENP properties ensuring higher safety. Therefore, the size 
distribution within an ENP batch should ideally not exceed 20 % (PDI 0.2). Finally, 
most of the therapeutic candidates launched for approval by authorities are not 
successful due to contaminations most prominently introduced during synthesis. Due 
to sterility issues bacteria and mycoplasma adhering to the surface are most often the 
prime reason for rejection of the formulation by regulators. 
Determining these seven physico-chemical parameters for every ENP formulation 
provides the needed information to draw the correct conclusions from in vitro or in vivo 
toxicity study results when trying to link an adverse outcome to a specific ENP feature. 
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In vitro screening of ENP toxicity 
Screening the effects that ENP can have on in vitro systems is the most common 
approach of gaining knowledge in nanotoxicological research. Depending on the goal 
of the screening, the main challenges are the choice of the optimal cell-based system, 
ENP type, ENP dose, and incubation parameters (e.g. time, temperature). 
Most nanotoxicological screenings bare the motivation of detecting a reaction from the 
biological test system after interacting with an ENP. Therefore, high ENP doses, 
optimized treatment conditions, and appropriate cell types are chosen to achieve this 
goal. 
A different approach should be used when determining the toxic potential of an ENP 
designed for therapeutic use. Here, the cellular model(s) should reflect the tissue most 
likely to be exposed to the therapeutic ENP in question. Furthermore, testing a dose 
range spanning across multiple orders of magnitude is necessary to determine the 
specific ENP associated adverse effects, the dose levels at which no adverse effect 
(NOAEL) and the lowest adverse effect (LOAEL) are encountered. Finally, ENP toxicity 
is time-dependent requiring a series of experiments in which the occurrence of possible 
adverse effects is screened for in defined intervals. 
Since there are no defined guidelines on how to examine the toxicity of ENP for medical 
purposes, the array of toxic effects that should be monitored is not demarcated.  
The extensive study described in Chapter I (pages 23 – 35)62 is an example of how 
the principal adverse effects caused by ENP can be screened and interpreted. The 
study shows that generation of ROS and significant cell death in form of apoptosis and 
necrosis is the results of SiNP uptake in human endothelial cells. Furthermore, 
signaling experiments revealed that ROS triggers the activation of the inflammation 
and apoptosis linked JAK/STAT pathway before apoptotic activity is detected. At the 
same time, cellular defense mechanisms such as the activation of NFκ-B could not be 
observed. Even though the production of the apoptosis-inhibiting protein Survivin 
meant that the immune defense of endothelial cells was partly functioning, incubated 
cells were not able to manage the prevailing ENP exposure. An exception was found 
at lowest ENP doses where the modulation of MHC class I, low ROS generation and 
no significant cell viability decrease suggested a functioning cellular defense after more 
than 48h of incubation. These observations point out the capability of selectively 
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triggering signaling pathways with differently modified ENP. Notably, these 
observations are restricted to acute adverse effects triggered by ENP. 
In the specific case of evaluating the toxic potential of a formulation designed for 
therapeutic use, monitoring further parameters (e.g. intracellular persistence, 
hemolysis) with additional cell-based systems is a prerequisite (Chapter IV; pages 75 
– 119). 
To monitor the ability of ENP to cause chronic toxicity on the other hand, in vivo 
screenings are a necessity. 
Alternative in vivo screening tool for nanotoxicology 
Due to several key characteristics the zebrafish embryo model has emerged as a 
potential in vivo model for nanotoxicology. Transparency, fast development, and small 
size make this animal a promising prospect for toxicological studies with the possibility 
of implementing HTS as well. Moreover, their extensive use in developmental biology 
has led to the availability of an enormous amount of transgenic lines to monitor angio-
, organo-, or immunogenesis as well as the routine use of microinjection. Finally, the 
zebrafish is a vertebrate with close genome homology to the human (especially to the 
immune system). 
In Chapters II & III (pages 36 – 45 & 46 – 74) the zebrafish embryo is used as an 
alternative in vivo model system, firstly to monitor the safety and biodistribution of ENP 
and secondly to exploit its use as nanotoxicological tool. 
The stability and activity of PLGA nanoparticles were monitored using the zebrafish 
embryo model to verify their biomedical use in Chapter II (pages 36 – 45)111. The study 
revealed that the zebrafish embryo is an ideal small animal model for the monitoring 
of fluorescently labeled ENP. Furthermore, the stability of ENP formulations can be 
observed over days, proving the versatility of the model. Due to the possibility of 
observing the biodistribution of fluorescent ENP the behavior of an ENP presents 
information on the safety of the formulations, further supporting the use of the zebrafish 
in nanotoxicological studies and nanosafety assessments160. 
Biodistribution is one crucial parameter that needs to be investigated for ENP designed 
for therapeutic use. As described previously, this is possible for fluorescently labeled 
ENP after injection into the zebrafish. However, tracing non-labeled ENP is not as 
straightforward. However, this would be highly beneficial, especially for therapeutic 
ENP candidates.  
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Thus, monitoring the biodistribution of AuNP and SPIONs after injection into zebrafish 
embryos was investigated in Chapter III (pages 46 – 74). Different techniques (bright 
field microscopy, computer tomography, histology) were used to gain an overview of 
possibilities to monitor ENP biodistribution in vivo. The outcome of the study suggested 
that commercial microscopy techniques did not represent a valid alternative as the 
ENP could not be distinguished with certainty. Histological investigations had proven 
not to be suitable either. Despite its diminutive size the zebrafish had to be sectioned 
into a number of samples exceeding the possibility of whole-body evaluations. 
However, SRµCT was found to pose a valid alternative, as the biodistribution of non-
labeled ENP was able to be monitored throughout an entire organism for the first time. 
The insights provided by this novel combination of analysis technique and animal 
model further underline the value of the zebrafish animal model for nanotoxicology. 
However, the intention should not be to replace existing animal models with the 
zebrafish. This model should find its application as an early in vivo screening tool to 
bridge the gap from cell-based investigations to higher organisms such as the mouse 
or rat. Due to its physical features and possibility of HTS the zebrafish embryo could 
serve as a time- and cost-effective alternative for routine toxicity screening processes. 
Shortage of safety guidelines for nanoparticles designed for therapeutic use 
Although being aware of the shortage of nano-specific regulatory guidelines, 
authorities have not decided on how nanosafety should be regulated. From a 
regulatory point of view, there are four major issues responsible for this shortage: 
 
• Analytics: No robust and effective toolbox is available to characterize 
nanomaterials and quantify ENP exposure in test systems. 
• Screening methods in vivo: Specific methods to be integrated into a 
test and risk assessment strategy are inexistent and must be identified. 
• Reference System: Lack of reference ENP to validate test and risk 
assessment strategies ensuring robust results. 
• Grouping: Strategies to differentiate nanomaterials and to group 
similar materials are controversial. 
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Combining the results and insights obtained in Chapters I – III (pages 23 - 74) a 
proposal for a preclinical safety guideline for injectable nanomedicines was generated. 
This approach discussed in Chapter IV (pages 75 – 119) highlights the importance of 
application-specific safety assessment of ENP. Furthermore, the importance of distinct 
physico-chemical characterization is discussed as well as the choice of in vitro test 
systems, analysis techniques, and assay protocols. The strategy is based on the intent 
of fast and application-oriented decision making, including a novel definition for ENP 
designed for injection (iNP) as well as a novel hazard assessment approach. ENP 
interactions in this case are based on the two fundamental events prone to trigger 
nanotoxicological outcomes: cellular uptake and intracellular persistence. Depending 
on the levels of cellular uptake and intracellular persistence the examined ENP are 
categorized into one of four different classes. Hazard assessment for each class 
consists of a specific assay cascade to ensure maximum safety of the ENP before 
clinical trials. This preclinical safety guideline is the first of its kind, as there are no 
nanomedicine specific approaches existent and none of the existing safety strategies 
cover the evaluation of ENP exposure specifically after injection. 
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Outlook 
ENP have successfully broken onto the scene as promising alternatives for multiple 
medical applications. There use as DDS, diagnostic tools, and theranostic applications 
has stimulated an ever-growing community of researchers to tackle more common 
medical issues such as cancer, Alzheimer, or iron deficiency. To help pave the way for 
the successful achievement of these goals several efforts in nanotoxicology and 
nanosafety are being made. 
Introduction of standardized in vitro and in vivo characterization techniques and test 
systems (e.g. µCT and zebrafish embryo) would help greatly to generate less 
contradictory knowledge on the interactions of ENP with biological targets. 
Furthermore, this would lead to a more uniform view on how to regulate these 
promising materials and in turn accelerate the implementation of standard testing 
protocols. 
Institutions such as the US Nanotechnology Characterization Laboratory (US NCL) 
and the European Nanomedicine Characterization Laboratory (EU NCL) have begun 
to set up assay cascades for the testing of ENM that are intended for medical 
applications available for the public. Furthermore, they are consulted by regulatory 
authorities and manufacturers alike for the assistance with characterization and safety 
testing of ENM. In the future such institutions will have gained extensive knowledge of 
the intentions of both parties alongside developing an expertise in specific ENM safety 
evaluation, which in turn can be accessed by the public. Consequent use of their 
expertise would lead to a more uniform approach of testing across the field of 
nanotoxicology providing more comparable data and focused trouble-shooting. 
In their most recent communication on nano-related definitions, the FDA has stated 
that it could be favorable to regulate ENM in an application-orientated manner, which 
may help to clear up prevailing confusion and controversial views on the topic of 
nanosafety. This statement shows that a change of thinking is underway where the 
solution of successfully regulating ENM is no longer a one strategy approach, but 
where it is advisable that certain applicatory fields promote their own distinct regulation 
of ENM. For the field of nanomedicine this would be highly favorable. 
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Conclusion 
Throughout this work the main parameters important for the safety of ENP designed 
for therapeutic use were assessed, analyzed, and discussed. This provided several 
novelties in cell signaling, in vivo imaging, and in hazard assessment. It could be shown 
that differently charged nanoparticles can selectively trigger signaling pathways in a 
dose and time-dependent manner. Different silica-based ENP were shown to activate 
the JAK/STAT pathway and modulate of MHC class I. The correlation between these 
findings and further adverse effects such as generation of ROS, apoptosis, and 
necrosis has underlined the hypothesis that after nanoparticle uptake specific 
toxicological cascades are triggered. Furthermore, the implementation of the zebrafish 
embryo model into safety and biodistribution studies proved that this novel vertebrate 
model would be an ideal complementary in vivo system for nanotoxicological studies. 
By combining the zebrafish with powerful synchrotron-based computer tomography the 
biodistribution of non-labeled ENP administered in therapeutic doses could be 
visualized for the first time in an entire animal model. The combination of all obtained 
results and insights led to the proposal of a safety guideline specifically for injectable 
nanoparticles incorporating the most important factors of physico-chemical 
characterization, ENP interaction, and hazard assessment. This application-oriented 
approach is based on exclusion criteria, facilitates regulatory decision-making, and 
incorporates standardized assay protocols to form a robust and highly feasible 
strategy. The proposal represents the very first safety guideline issued specifically for 
the preclinical development of nanomedicines.  
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• Communication training and enhancement of problem-solving skills 
 
06/2012 – present  Board Member Head of Junior Handball, HB Blau Boys Binningen 
• Coordination of junior teams and their staff (approx. 100 individuals) 
• Coordination of yearly budget and expenses (J+S Coach Diploma) 
• Club representative for youth sports in the talent-pool HSG Leimental 
 
03/2003 – 6/2018  Handball Team Coach, HB Blau Boys Binningen 
• Diploma C adult/youth handball and Diploma children’s sports/handball 
 
 
Languages 
Spoken & written German: native  French: intermediate (level B2) 
 English: native  Spanish: intermediate (level B2) 
 
 
Computer Skills 
Software experience MS Office, Origin, FlowJo, Gimp, ImageJ, JMP, Subway, BioELN, BSM 
 
 
Recreational interests 
• team handball, golf, and soccer 
• travelling, cooking, and board games 
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Publications and granted proposals 
09/2018 Preclinical Hazard Evaluation Strategy for Nanomedicines 
Siegrist S., Cörek E., Detampel P., Wick. P., Sandström J., Huwyler J.; J. of 
Nanotoxicology 
 
08/2018 Propagation-basedX-ray Phase Contrast Microtomographyof Zebrafish 
Embryos to Understand Drug Delivery 
Schulz G., Cörek E., Siegrist S., Thalmann P., Dehyle A., Rack A., Huwyler 
J., Müller B.; Microsc. Microanal. 24 (Suppl 2), 2018 
 
09/2017 Removing ring artefacts from synchrotron radiation-based hard X-ray 
tomography data 
Thalmann P., Bikis C., Schulz G., Paleo P., Mirone A., Rack A., Siegrist S., 
Cörek E., Huwyler J., Müller B.; Proc. SPIE 
 
09/2017 Granted proposal for beam time at the Paul-Scherrer Institue (PSI) in Viligen, 
Switzerland. Implementing synchrotron radiation phase-contrast micro-
computed tomography for monitoring the biodistribution differently coated iron 
nanoparticles upon injection into zebrafish embryos in vivo. 
 
05/2017 Selective stimulation of the JAK/STAT signaling pathway by silica 
nanoparticles in human endothelial cells. 
Siegrist S., Kettiger H., Fasler-Kan E., Huwyler J.; Toxicol. In Vitro 
 
04/2017  Immobilization of Enzymes on PLGA Sub-Micrometer Particles by 
Crosslinked Layer-by-Layer Deposition. 
Sieber S., Siegrist S., Schwarz S., Porta F., Schenk SH., Huwyler J.; 
Macromol. Biosci. 
 
02/2016 Granted proposal for beam time at the European Synchrotron Radiation 
Facility (ESRF) in Grenoble, France. Implementing synchrotron radiation 
phase-contrast micro-computed tomography for the visualization of silica, 
gold, and iron nanoparticles upon injection into zebrafish embryos in situ. 
 
 
Manuscripts under review 
 
Biodistribution of metal-based nano-particles in a small vertebrate model traced by synchrotron radiation 
micro-tomography 
Siegrist S., Cörek E., Fluder P., Klados K., Bikis C., Detampel P., Thalmann P., Schulz G., Puchkov 
M., Alexiou C., Müller B., Huwyler J. 
 
High-Affinity Carbohydrate-Lectin Interactions: How Nature Makes it Possible 
Zihlmann P., Jiang X., Sager C.P., Fiege B., Jakob R.P., Siegrist S., Zalewski A., Rabbani S., Eris D., 
Silbermann M., Pang L., Muhlethaler T., Sharpe T., Maier T., Ernst B. 
 
